Showing 1 - 5 results of 5 for search 'Emilio Fonseca', query time: 0.01s Refine Results
  1. 1
    Inflammatory Mesenteric Disease and Sarcoidosis-like Reaction in a Patient with Lung Adenocarcinoma Who Received Pembrolizumab: Paraneoplastic Syndrome, Secondary to Checkpoint Inhibitor or Chance Finding?

    Inflammatory Mesenteric Disease and Sarcoidosis-like Reaction in a Patient with Lung Adenocarcinoma Who Received Pembrolizumab: Paraneoplastic Syndrome, Secondary to Checkpoint Inh... by Luis Posado-Domínguez, María Escribano-Iglesias, Lorena Bellido-Hernández, Johana Gabriela León-Gil, María Asunción Gómez-Muñoz, Felipe Gómez-Caminero López, María Martín-Galache, Sandra M. Inés-Revuelta, Emilio Fonseca-Sánchez

    Published 2024-11-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Impact of functional re-education and environmental adaptation in cancer patients with respiratory pathology: Study protocol.

    Impact of functional re-education and environmental adaptation in cancer patients with respiratory pathology: Study protocol. by Eduardo Jose Fernandez-Rodriguez, Maria Isabel Rihuete-Galve, Alberto Garcia-Martin, Celia Sanchez-Gomez, Fausto Jose Barbero-Iglesias, Roberto Mendez-Sanchez, Ana Silvia Puente-Gonzalez, Susana Saez-Gutierrez, Emilio Fonseca-Sanchez, Juan Jesus Cruz-Hernandez

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Evaluation of the effect of metformin as a radiosensitiser in solid tumours: A systematic review

    Evaluation of the effect of metformin as a radiosensitiser in solid tumours: A systematic review by Elísabet González del Portillo, Alejandro Olivares-Hernández, Luis Corral Gudino, Laura Corvo Félix, Lorena Bellido Hernández, Luis Posado Domínguez, David León Jiménez, Rogelio González Sarmiento, Edel del Barco Morillo, Emilio Fonseca Sánchez, José Pablo Miramontes-Gonzáleze

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer

    PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer by Eduardo Terán, Rebeca Lozano, César A. Rodríguez, Mar Abad, Luis Figuero, José Antonio Muñoz, Belén Cigarral, Aline Rodrígues, Magdalena Sancho, M. Asunción Gómez, Daniel Morchón, Juan Carlos Montero, José María Sayagués, M. Dolores Ludeña, Emilio Fonseca

    Published 2024-09-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Corrigendum to “Evaluation of the effect of metformin as a radiosensitiser in solid tumours: A systematic review” [Clin. Translat. Radiat. Oncol. 52 (2025) 100930]

    Corrigendum to “Evaluation of the effect of metformin as a radiosensitiser in solid tumours: A systematic review” [Clin. Translat. Radiat. Oncol. 52 (2025) 100930] by Elísabet González del Portillo, Alejandro Olivares-Hernández, Luis Corral-Gudino, Laura Corvo Félix, Lorena Bellido Hernández, Luis Posado Domínguez, David León Jiménez, Rogelio González Sarmiento, Edel del Barco Morillo, Emilio Fonseca Sánchez, José Pablo Miramontes-González

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: